HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B

• Daniel C. Kirouac ,

  Contributed equally to this work with: Daniel C. Kirouac, Jinyan Du

  Current address: Genentech Research and Early Development, South San Francisco, California, United States of America

  Affiliation Discovery, Merrimack Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Jinyan Du ,

  Contributed equally to this work with: Daniel C. Kirouac, Jinyan Du

  * E-mail: jdu@merrimack.com

  Affiliation Discovery, Merrimack Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Johanna Lahdenranta,

  Affiliation Discovery, Merrimack Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Matthew D. Onsum,

  Current address: Seattle Genetics, Bothell, Washington, United States of America

  Affiliation Discovery, Merrimack Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Ulrik B. Nielsen,

  Current address: Torque Therapeutics, Inc., Cambridge, Massachusetts, United States of America

  Affiliation Discovery, Merrimack Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Birgit Schoeberl,

  Affiliation Discovery, Merrimack Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯
• Charlotte F. McDonagh

  Affiliation Discovery, Merrimack Pharmaceuticals, Cambridge, Massachusetts, United States of America

  ⨯